Chattem Report issue

Contributed to NME For profit Phase 3
Founded: Chattanooga TN United States (1879)
Status: Acquired by Sanofi-Aventis (2009)

Organization Overview

First Clinical Trial
2012
NCT01744106
First Marketed Drug
1951
selenium
First NDA Approval
1951
selenium
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CHATTEM | Chattem, Inc.

Active Ingredients

Marketed Drugs (2)

doxylamine (1978)

selenium (1951 NDA)

Drugs in Phase 3 Trials (1)

pseudoephedrine (Benylin) (1 trial)

Indications

Approved Indications


 

Dermatitis, Seborrheic

Experimental Indications (Clinical Trials, Phases 1-4)


 

Common Cold (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1